Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

NCT05417594 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05417594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05417594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 24, 2022
Completion date
February 7, 2028
Enrollment
695 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies